Oramed wins Japanese patent approval, nears insulin pill Phase II; Activaero sees positive results in childhood asthma trials;

> Oramed ($ORMP) recieved a Japanese patent for its technology that allows the oral administration of drugs rather than their injected counterparts, including the long-awaited oral insulin pill for which the company is approaching Phase II trials. Release

> Activaero GmbH achieved positive results in a Phase II trial of its childhood asthma treatment that combines liquid budesonide and the company's controlled inhalation system. Release

> Hospira ($HSP), Delcath Systems ($DCTH), Valeant Pharmaceuticals ($VRX) and Alkermes ($ALKS)--all companies with a hand in drug delivery--are under the microscope in a study evaluating the impact of the Affordable Care Act. Release

> Medimetrics and NIZO's drug-delivering, remote-controlled pill IntelliCap, may now also be used as a mapping system of the gastrointestinal tract, detecting links to diseases such as obesity and diabetes. More

> SteadyMed Therapeutics received a $3 million term loan credit facility from Square 1 Bank. SteadyMed's lead product is the PatchPump, which allows the delivery of liquid-based drugs though a programmable system. Story

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.